Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363373 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL840939 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL14304968 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL12000798 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL5452846 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL295573 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL23845860 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL137622 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL13460643 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 | |
| SCHEMBL13460354 | 1.00 | UGCG (1.00) | UGCGKMT2AMEN1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090202439-A1 | Methods for treatment of angiogenesis | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-08-13 | — | — | US | claimed |
| US-20230165803-A1 | BIOPOLYMER-ENCAPSULATED GLYCOSYLTRANSFERASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING DIABETES AND CARDIAC INDICATIONS | UNIV JOHNS HOPKINS (US) | 2023-06-01 | — | — | US | disclosed |
| US-20210386678-A1 | BIOPOLYMER-ENCAPSULATED GLYCOSYL TRANSFERASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING DIABETES AND CARDIAC INDICATIONS | UNIV JOHNS HOPKINS (US) | 2021-12-16 | — | — | US | disclosed |
| US-9828349-B2 | 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity | EXONHIT THERAPEUTICS SA (FR) | 2017-11-28 | — | — | US | disclosed |
| US-9828349-B2 | 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity | EXONHIT THERAPEUTICS SA (FR) | 2017-11-28 | — | — | US | disclosed |
| US-20170119683-A1 | BIOPOLYMER-ENCAPSULATED GLYCOSYL TRANSFERASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING DIABETES AND CARDIAC INDICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-05-04 | — | — | US | disclosed |
| US-9399628-B2 | 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity | ALLERGAN, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9399628-B2 | 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity | ALLERGAN, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9314466-B2 | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds | ALLERGAN, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9314466-B2 | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds | ALLERGAN, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-6255336-B1 | REDUCING CONCENTRATION OF GLYCOSPHINGOLIPIDS; SYNTHASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2001-07-03 | — | — | US | disclosed |
| US-6228889-B1 | Methods for treatment of conditions associated with lactosylceramide | JOHNS HOPKINS UNIVERSITY | 2001-05-08 | — | — | US | disclosed |
| WO-2001004108-A1 | AMINO CERAMIDE-LIKE COMPOUNDS AND THERAPEUTIC METHODS OF USE | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2001-01-18 | — | — | WO | disclosed |
| US-6051598-A | TREATING A PATIENT HAVING SPHINGOLIPIDOSIS BY REDUCING GLYCOSPHINGOLIPID SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2000-04-18 | — | — | US | disclosed |
| US-6040332-A | INHIBIT GLUCOSYL CERAMIDE (GLCCER) FORMATION BY INHIBITING THE ENZYME GLCCER SYNTHASE, THEREBY LOWERING THE LEVEL OF GLYCOSPHINGOLIPIDS. | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2000-03-21 | — | — | US | disclosed |
| US-6030995-A | 1-PYRROLIDINO-2-FATTY CARBOXYAMIDO-3-HYDROXY-3-ALKYL- OR ARYLPROPANES; INHIBITORS OF THE GLUCOSYL CERAMIDE SYNTHETASE, THEREBY LOWERING THE LEVEL OF GLYCOSPHINGOLIPIDS; METABOLIC DISORDERS, E.G., TAY-SACHS, GAUCHER'S AND FABRY'S DISEASES, | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2000-02-29 | — | — | US | disclosed |
| US-5972928-A | ADMINISTERING AN ANTIGROWTH AGENT | JOHNS HOPKINS UNIVERSITY (US) | 1999-10-26 | — | — | US | disclosed |
| US-5952370-A | ADMINISTERING A 1-ALKYL OR ARYL OR ALICYCLIC-2-ALKYLOYLAMINO-3-PYRROLIDINO-1-PROPANOL DERIVATIVE TO TREAT CONDITION OR DISEASES ASSOCIATED WITH GLYCOSYL CERAMIDE FORMATION; ENZYME INHIBITOR | THE REGENTS OF UNIVERSITY OF MICHIGAN (US) | 1999-09-14 | — | — | US | disclosed |
| US-5945442-A | Amino ceramide-like compounds and therapeutic methods of use | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1999-08-31 | — | — | US | disclosed |
| US-5916911-A | ANTITUMOR | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1999-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210386678-A1 | BIOPOLYMER-ENCAPSULATED GLYCOSYL TRANSFERASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING DIABETES AND CARDIAC INDICATIONS | PNLIP, TNNT2, UGGT1 | UGCG 45/4885KMT2A 1822/4885MEN1 3270/4885 |
| US-20090202439-A1 | Methods for treatment of angiogenesis | B4GALT1, FLT1, FLT4 | UGCG 5/4885KMT2A 1679/4885MEN1 4477/4885 |
| US-20230165803-A1 | BIOPOLYMER-ENCAPSULATED GLYCOSYLTRANSFERASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING DIABETES AND CARDIAC INDICATIONS | PNLIP, TNNT2, UGGT1 | UGCG 38/4885KMT2A 1730/4885MEN1 2578/4885 |
| US-20170119683-A1 | BIOPOLYMER-ENCAPSULATED GLYCOSYL TRANSFERASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING DIABETES AND CARDIAC INDICATIONS | OGT, UGGT1, TNNT2 | UGCG 48/4885KMT2A 1092/4885MEN1 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.